Development of novel PAR2 antagonists to treat inflammatory disease

Project: ResearchResearch (Institute)

Description

Based on the recently published PAR2 crystal structure, a novel series of PAR2 antagonists were developed - namely the AZ series. However these require further target validation and elucidation of there pharmacological properties, and from these novel derivatives will be developed.

Layman's description

Inhibiting the GPCR receptor PAR2 for the treatment of arthritis and inflammatory disease

Key findings

AZ-series appears to be a selective PAR2 antagonist, capable of inhibiting several downstream signalling pathways. Further work ex-vivo is on-going.
Short titlePAR2 antagonists
StatusActive
Effective start/end date5/02/1831/07/21